Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Therapeutic Efficacy Between Lobeglitazone and Pioglitazone as Initial Triple Therapy With Metformin and Sitagliptin in Drug-naïve Type 2 Diabetic Patients

Next Previous
Trial Profile

Comparison of Therapeutic Efficacy Between Lobeglitazone and Pioglitazone as Initial Triple Therapy With Metformin and Sitagliptin in Drug-naïve Type 2 Diabetic Patients

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lobeglitazone (Primary) ; Metformin; Pioglitazone; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 29 Mar 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
  • 29 Mar 2021 Planned primary completion date changed from 30 Oct 2020 to 31 Dec 2021.
  • 04 Oct 2019 Planned End Date changed from 1 Dec 2018 to 31 Dec 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top